
Rate Of Return
AMD Gain HunterDon't compare small molecules with large molecules, small molecule drugs have low cost and fast production, as long as the effect is acceptable they can capture the low-income market. Additionally, Eli Lilly's large molecule efficacy currently leads Novo Nordisk, and the oral large molecule launch is slower than Novo Nordisk. Although I'm a shareholder of NVO, I have to say this chart is unfair to LLY.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.


